On Wednesday, the Food and Drug Administration approved a highly effective, injectable drug to help prevent the transmission of HIV, according to its manufacturer, Gilead Sciences. The drug, lenacapavir, will be sold under the name Yeztugo.

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement. “Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic.”